| Literature DB >> 26674922 |
Emma Louise Beckett1, Charlotte Martin2, Jeong Hwa Choi2, Katrina King3, Suzanne Niblett3, Lyndell Boyd2, Konsta Duesing4, Zoe Yates5, Martin Veysey3, Mark Lucock2.
Abstract
BACKGROUND: Free circulating microRNA (miRNA) in serum may be valuable biomarkers for disease diagnosis and prognosis. miR-21, the archetypal oncogenic miRNA, has been proposed as a biomarker for colorectal cancer and its benign precursor, adenomatous polyps. However, it is now becoming clear that circulating miRNA profiles may be sensitive to lifestyle and environmental influences. Dietary components involved in one-carbon metabolism are particularly well placed to modulate miRNA expression through an influence on DNA methylation pathways.Entities:
Keywords: AP, Adenomatous polyps; Adenomatous polyps; CRC, Colorectal cancer; Colorectal cancer; Folate; MiR-21; MicroRNA
Year: 2015 PMID: 26674922 PMCID: PMC4661713 DOI: 10.1016/j.bbacli.2015.06.006
Source DB: PubMed Journal: BBA Clin ISSN: 2214-6474
Fig. 1Serum miR-21 expression in adenomatous polyp cases versus controls in A) females (n = 144) and B) males (n = 109). REU = relative expression units.
Selected characteristics of the primary cohort, cases vs. controls, stratified by sex.
| Female | Male | Female vs male | ||||||
|---|---|---|---|---|---|---|---|---|
| Case n = 26 | Control n = 118 | Case n = 30 | Control n = 79 | |||||
| Age (years) | 65.5 ± 1.7 | 59.3 ± 1.1 | 0.004 | 67.0 ± 2.1 | 63.4 ± 1.5 | 0.16 | 0.58 | 0.03 |
| Age range | 46–82 | 18–82 | 44–89 | 28–88 | ||||
| Smoking history | ||||||||
| Current | 9 (6.3) | 27 (18.8) | 8 (7.3) | 18 (16.5) | ||||
| Ex | 6 (4.2) | 37 (25.7) | 9 (8.3) | 42 (38.5) | ||||
| Never | 11 (7.6) | 54 (37.5) | 0.42⁎ | 13 (11.9) | 19 (17.4) | 0.07 | 0.76 | 0.003 |
| MiR-21 (REU) | 1.85 ± 0.70 | 0.07 ± 0.27 | 0.02 | − 0.07 ± 0.40 | 0.50 ± 0.33 | 0.26 | 0.02 | 0.31 |
| Red blood cell folate (μmol L− 1) | 1.29 ± 0.12 | 0.93 ± 0.04 | 0.009 | 0.89 ± 0.07 | 1.1 ± 0.05 | 0.06 | 0.006 | 0.08 |
| Serum B12 (nmol L− 1) | 0.29 ± 0.02 | 0.28 ± 0.01 | 0.80 | 0.27 ± 0.02 | 0.27 ± 13.11 | 0.96 | 0.60 | 0.53 |
| Cysteine (mmol L− 1) | 0.26 ± 0.01 | 0.26 ± 0.04 | 0.98 | 0.27 ± 0.08 | 0.27 ± 0.05 | 0.65 | 0.27 | 0.73 |
| Homocysteine (μmol L− 1) | 12.41 ± 0.79 | 12.01 ± 0.40 | 0.65 | 13.78 ± 1.21 | 13.62 ± 0.52 | 0.90 | 0.35 | 0.02 |
Mean ± SEM.
Count (%total).
p-Value χ2.
Selected characteristics of the secondary cohort, stratified by sex.
| Female n = 362 | Male n = 287 | ||
|---|---|---|---|
| Age (years) | 60.4 ± 0.96 | 64.4 ± 1.21 | 0.35 |
| Age range | 18–84 | 28–89 | |
| Smoking history | |||
| Current | 10 (0.02) | 11 (0.02) | |
| Ex | 122 (0.19) | 180 (0.28) | |
| Never | 230 (0.35) | 96 (0.15) | < 0.0001 |
| MiR-21 (REU) | − 0.42 | − 0.09 | 0.0065 |
| Red blood cell folate (μmol L− 1) | 1.29 | 1.23 | 0.07 |
| Serum B12 (nmol L− 1) | 0.24 | 0.22 | 0.05 |
| Homocysteine (μmol L− 1) | 10.07 | 11.34 | 0.01 |
Mean ± SEM.
Count (%total).
p-Value χ2.
Fig. 2The relationship between serum miR-21 and erythrocyte folate in A) females (r2 = 0.248, β = 3.13, p = 0.0001, n = 144) and B) males (r2 = 0.05, β = 1.25, p = 0.03, n = 109) from the primary cohort and C) females (r2 = 0.140, β = 1.46, p < 0.0001, n = 362) and D) males (r2 = 0.160, β = 1.16, p < 0.0001, n = 287) from the secondary cohort. REU = relative expression units.
Fig. 3Serum miR-21 expression by: MTHFR-C677T genotype in A) females and B) males; DHFR-19 del genotype in C) females and D) males; and, MSR-A66G genotype in E) females and F) males of the primary cohort. REU = relative expression units; “+” = no deletion, “−” = 19 bp deletion.
Fig. 4Serum miR-21 expression in colorectal cancer cell line cultures with deficient, control and excess levels of folic acid in A) CACO2, B) HT29, and C) HCT116 cells. REU = relative expression units, normalized to percentage proliferation. Data shown is mean ± standard error of mean. 3 replicates per group.